SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-006623
Filing Date
2022-02-24
Accepted
2022-02-24 17:19:16
Documents
14
Period of Report
2022-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10034431_8k.htm   iXBRL 8-K 26355
2 EXHIBIT 99.1 brhc10034431_ex99-1.htm EX-99.1 110229
6 image00002.jpg GRAPHIC 4258
  Complete submission text file 0001140361-22-006623.txt   292022

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20220224.xsd EX-101.SCH 3935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20220224_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20220224_pre.xml EX-101.PRE 16050
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10034431_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 22672682
SIC: 2834 Pharmaceutical Preparations